Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Short-term Investments (2022 - 2025)

Oramed Pharmaceuticals' Short-term Investments history spans 4 years, with the latest figure at $11.0 million for Q4 2025.

  • For Q4 2025, Short-term Investments changed N/A year-over-year to $11.0 million; the TTM value through Dec 2025 reached $11.0 million, changed N/A, while the annual FY2025 figure was $11.0 million, N/A changed from the prior year.
  • Short-term Investments reached $11.0 million in Q4 2025 per ORMP's latest filing, up from $4.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $121.1 million in Q3 2022 to a low of $99000.0 in Q2 2023.
  • Average Short-term Investments over 4 years is $55.9 million, with a median of $57.5 million recorded in 2025.
  • Peak YoY movement for Short-term Investments: crashed 99.9% in 2023, then soared 66774.75% in 2024.
  • A 4-year view of Short-term Investments shows it stood at $111.5 million in 2022, then dropped by 14.56% to $95.3 million in 2023, then plummeted by 55.14% to $42.7 million in 2024, then crashed by 74.31% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Short-term Investments are $11.0 million (Q4 2025), $4.0 million (Q3 2025), and $57.5 million (Q2 2025).